Immuntherapie von Kopf-Hals-Tumoren
Author:
Publisher
Springer Science and Business Media LLC
Subject
Otorhinolaryngology
Link
http://link.springer.com/content/pdf/10.1007/s00106-019-00761-8.pdf
Reference18 articles.
1. Alfieri S, Ferrara R, Calareso G et al (2019) Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI). JCO 37:6029–6029
2. Bauman JE, Saba NF, Wise-Draper TM et al (2019) CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). JCO 37:6025–6025
3. Biel MA, Gillenwater AM, Cognetti DM et al (2019) A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). J Clin Oncol 37:TPS6094–TPS6094
4. Brand TM, Hartmann S, Bhola NE et al (2018) Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res 78:2383–2395
5. Burtness B, Harrington KJ, Greil R et al (2018) LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann Oncol. https://doi.org/10.1093/annonc/mdy424.045
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Protein-Based Oncopanel as Addition to Target Sequencing in Head and Neck Squamous Cell Carcinoma to Individualize Treatment Decisions;International Journal of Molecular Sciences;2022-12-13
2. Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies;Critical Reviews in Oncology/Hematology;2022-02
3. Prospective longitudinal study of immune checkpoint molecule ( ICM ) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma ( HNSCC );International Journal of Cancer;2020-12-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3